Kite Pharma to Highlight Cancer Immunotherapy T Cell Manufacturing Process at 2014 ASCO Annual Meeting

Santa Monica, CA – May 30, 2014 – Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the Company will provide details on key features of the rapid, 6-day manufacturing process that is expected to underlie its most advanced personalized cancer immunotherapy program.  The technology is expected to underpin a Kite clinical trial in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL), a highly refractory and aggressive blood cancer, which Kite expects to commence in early 2015.  Elements of Kite's manufacturing process will be featured in a poster presentation during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, May 30 to June 3, 2014.

ASCO 2014 Poster Presentation

  • Title:  Rapid cell expansion (RACE) technology for production of engineered autologous T-cell therapy: Path toward manageable multicenter clinical trials in aggressive NHL with anti-CD19 CAR.
  • Authors:  Marc Better1, Omar Pugach1, Lily Lu2, Robert Somerville2, Sadik Kassim2, James Kochenderfer2, Steven A. Rosenberg2, Margaret A. Marshall1, Adrian Bot1, Keith B. Nolop1, Margo Roberts1, Steven Feldman2.  [ 1 = Kite Pharma; 2 = National Cancer Institute ]
  • Abstract:  #3079
  • Poster:  #146
  • General Poster Session:  Developmental Therapeutics - Immunotherapy
  • Date and Location:  Sunday, June 1, 2014, 8:00am – 11:45am Central Time; S Hall A2

About Kite Pharma
Kite Pharma, Inc., is a privately held clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors.  In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT™ product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications.  Kite's management team has a proven track record of building successful biotechnology companies and successfully developing novel immunotherapies and other oncology treatments.  Kite is based in Santa Monica, CA.

###